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Separate prediction of intracerebral
hemorrhage and ischemic stroke
ABSTRACT
Objectives: To develop and validate 10-year cumulative incidence functions of intracerebral hem-
orrhage (ICH) and ischemic stroke (IS).
Methods: We used data on 27,493 participants from 3 population-based cohort studies: the Ath-
erosclerosis Risk in Communities Study, median age 54 years, 45%male, median follow-up 20.7
years; the Rotterdam Study, median age 68 years, 38% male, median follow-up 14.3 years; and
the Cardiovascular Health Study, median age 71 years, 41%male, median follow-up 12.8 years.
Among these participants, 325 ICH events, 2,559 IS events, and 9,909 nonstroke deaths
occurred. We developed 10-year cumulative incidence functions for ICH and IS using stratified
Cox regression and competing risks analysis. Basic models including only established nonlabora-
tory risk factors were extended with diastolic blood pressure, total cholesterol/high-density lipo-
protein cholesterol ratio, body mass index, waist-to-hip ratio, and glomerular filtration rate. The
cumulative incidence functions’ performances were cross-validated in each cohort separately
by Harrell C-statistic and calibration plots.
Results: High total cholesterol/high-density lipoprotein cholesterol ratio decreased the ICH rates
but increased IS rates (p for difference across stroke types ,0.001). For both the ICH and IS
models, C statistics increased more by model extension in the Atherosclerosis Risk in Communi-
ties and Cardiovascular Health Study cohorts. Improvements in C statistics were reproduced by
cross-validation. Models were well calibrated in all cohorts. Correlations between 10-year ICH
and IS risks were moderate in each cohort.
Conclusions: We developed and cross-validated cumulative incidence functions for separate pre-
diction of 10-year ICH and IS risk. These functions can be useful to further specify an individual’s
stroke risk. Neurology® 2014;82:1804–1812
GLOSSARY
ARIC5 Atherosclerosis Risk in Communities; BMI5 body mass index; CHS 5 Cardiovascular Health Study; CI5 confidence
interval; HDL-C 5 high-density lipoprotein cholesterol; HR 5 hazard ratio; ICH 5 intracerebral hemorrhage; IS 5 ischemic
stroke.
Stroke is the second leading cause of death and one of the major causes of disability in most
Western countries.1 The incidence of stroke steadily increases from middle age onward.
Although most strokes are ischemic strokes (IS), approximately 10% are intracerebral hemor-
rhages (ICHs), which have a higher case fatality than IS: 41.0% vs 14.3%.2
Multiple risk factors that influence stroke risk are well established and can be used to estimate an
individual’s stroke risk over a 10-year time period.3–6 Distinguishing the risk of stroke types, i.e.,
ICH vs IS, could be valuable for various reasons. First, risk factors may vary or may have different
or even opposing effects.7 Consequently, the likely effects of modifying these risk factors may vary
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per stroke type. Second, although antithrom-
botic therapy has a net preventive effect on
stroke by decreasing the occurrence of IS, it also
increases the risk of ICH.8 Therefore, decision-
making for antithrombotic therapy could be
improved by predicting ICH and IS risk sepa-
rately. Third, the consequences (e.g., the case
fatality) of both types differ and a more refined
risk communication can be facilitated.
In addition, established stroke risk scores
were developed using standard survival analy-
sis with censoring for competing death events.
Standard survival analysis will generally over-
estimate the cumulative incidence, because it
fails to consider those who die of nonstroke
causes as ineligible for development of stroke
events. Methods to adjust for competing risks
are now increasingly being used for cardiovas-
cular risk prediction.9 In this study, we aimed
to develop and validate separate prediction
models for estimation of the 10-year cumula-
tive incidences of ICH and IS.
METHODS Study design and population. We performed
a combined analysis of individual data from 3 population-based
cohort studies: the Atherosclerosis Risk in Communities
(ARIC) Study, the Rotterdam Study, and the Cardiovascular
Health Study (CHS).
The ARIC Study10 comprises 15,792 individuals aged 45 to 64
years at baseline recruited from 4 different regions in the United
States from 1987 to 1989. The Rotterdam Study11 consists of 7,983
inhabitants of Ommoord, Rotterdam, the Netherlands, aged 55
years and older. Baseline examinations were conducted from 1990
to 1993. In the CHS,12 individuals older than 65 years living in 4
US communities were recruited from the Health Care Financing
Administration (or Medicare) eligibility lists in 2 phases. First, 5,201
participants were recruited from 1989 to 1990. In a second wave,
687 African Americans were recruited from 1992 to 1993 leading to
a cohort of 5,888 participants. For details on baseline measurements
of the 3 studies, see appendix e-1 on the Neurology® Web site at
Neurology.org.
The subjects eligible for the current analysis were those without
prior stroke (n 5 15,297 in the ARIC cohort, n 5 7,546 in the
Rotterdam Study, n 5 5,639 in the CHS), who did not use anti-
coagulation (n5 15,222 ARIC Study, n5 7,177 Rotterdam Study,
n 5 5,572 CHS), and who did not have atrial fibrillation (n 5
15,217 ARIC cohort, n 5 6,910 Rotterdam Study, n 5 5,446
CHS) at baseline. The latter 2 exclusion criteria were used because
specific guidelines and prediction models already exist for these
patients.13 In addition, we excluded participants who were not
African American or Caucasian, leaving n 5 27,493 subjects (n 5
15,170 ARIC Study, n 5 6,910 Rotterdam Study, n 5 5,413
CHS) for the analysis.
Based on previous literature, we considered age, sex, African
American ethnicity, current smoking, systolic blood pressure,
antihypertensive medication use, diabetes mellitus, and history
of coronary heart disease as candidate predictors in a basic nonla-
boratory model for each stroke type.3–5,14–16 Subsequently, we
evaluated model extension by the following office-based risk
factors: diastolic blood pressure, total cholesterol, high-density
lipoprotein cholesterol (HDL-C), body mass index (BMI),
waist-to-hip ratio, and estimated glomerular filtration rate.4,5,7,15
Standard protocol approvals, registrations, and patient
consents. All studies received approval from medical ethical
committees, and participants gave written informed consent.
Outcome definitions. Details of outcome ascertainment are
described elsewhere17–19 and in appendix e-1. In brief, ARIC
outcomes were ascertained through yearly telephone interviews,
follow-up examinations, community hospital surveillance, and
reported deaths. In the Rotterdam Study, participants were
continuously monitored for events through automated linkage
of the study database with files from general practitioners and
the municipality. Medical records of nursing homes were also
evaluated. CHS outcomes were ascertained through 6 monthly
telephone interviews, surveillance of Health Care Financing
Administration Medicare Utilization files, and reported deaths.
For ICH, we excluded ascertained subarachnoid and trau-
matic hemorrhages. IS was defined as a combined endpoint of
classified ischemic and unspecified stroke as a proxy for true IS
events to avoid underestimation.20 Strokes were classified as ische-
mic if there was no evidence for other diagnoses based on imaging
and evident clinical features, or if there was surgical or autopsy
evidence of ischemia (also see table e-1). Any stroke was defined
as the sum of ICH and IS. Censoring date was December 31,
2009 for the ARIC Study, January 1, 2009 for the Rotterdam
Study, and June 30, 2008 for the CHS dataset.
Statistical analysis. Two separate prediction models for the 10-
year cumulative incidence of ICH and IS were developed using
Cox regression modeling and considering competing risks (see
appendix e-1 for more details). In addition, we developed an
“any stroke” model, which can be subdivided into an ICH and
IS component. The cause-specific Cox regression models were
stratified by study cohort and developed with time since study
entry as the time scale. In the basic models, effect modification by
sex was evaluated for age, systolic blood pressure, diabetes
mellitus, and history of coronary heart disease. An interaction
term for systolic blood pressure and antihypertensive
medication use was included.3,14 In the extended models, we
evaluated replacement of total and HDL-C variables by the
total cholesterol/HDL-C ratio and systolic by diastolic blood
pressure.21 Finally, we tested heterogeneity of effects across
studies by study-predictor interaction terms, and across stroke
types by type-predictor interaction terms in full extended models.
Discriminative ability was assessed using Harrell concordance
statistic (C statistic) adjusted for competing risks by setting the
follow-up time to the maximum value if competing death
occurred.22 Model calibration was assessed by calibration plots
and x2 statistics, comparing predicted with observed cumulative
incidences using the R “CumInc” function of the R “mstate”
library. Equal sized groups per study were made according to
age tertiles for ICH and quintiles for IS. To understand the
impact of using cumulative incidence functions instead of stan-
dard survival analysis, we compared the discriminative ability and
model calibration of these 2 statistical methods for ICH and IS
prediction.
For cross-validation, models were fit in 2 cohorts and evalu-
ated in the other. Reclassification by extending basic models
was assessed by the continuous net reclassification improve-
ment.23 Ninety-five percent confidence intervals (CIs) were esti-
mated by bootstrapping datasets with recalculation of the
observed cumulative incidences within each bootstrap sample.
Scatter plots showing the relationship between the ICH and IS
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components within any stroke risk were made for each dataset
using extended models. Finally, we constructed an Excel risk
calculator for the risk assessment of 10-year ICH, IS, and any
stroke (as a sum of ICH and IS) risks (appendix e-2). Total
cholesterol/HDL-C ratios are automatically calculated from total
cholesterol and HDL-C. To individualize absolute risk differen-
ces and numbers needed to treat for each stroke type and any
stroke events, estimated treatment effects expressed as hazard
ratios (HRs) can be added.9
Missing covariable values were imputed for each study sepa-
rately using single imputation with the R “aregImpute” function
of the R “Hmisc” library. Imputation models included all poten-
tial predictors and the log cumulative hazard for each outcome.
Hypothesis tests were 2-sided and decisions on selection of pre-
dictor main effects were made based on an improvement of the
Akaike Information Criterion after exclusion from a full model.
Interactions and nonlinear effects were included using a p value
,0.05. The effect of excluding predictors with highly significant
heterogeneous HRs (p , 0.01 for ICH, p , 0.001 for IS and
competing death) on cross-validated model performance was
evaluated in sensitivity analyses (see tables e-2 to e-6). We used
R version 2.14.2 for all statistical analyses.
RESULTS Study population. The baseline characteris-
tics of included ARIC (median age 54, 45% male),
Rotterdam Study (median age 68, 38% male), and
CHS (median age 71, 41% male) participants are
given in table 1. In total, 325 participants experienced
an ICH, 2,559 experienced an IS event, and 9,909
died from a competing death cause. The total number
of individuals with ICH was low, especially in the
ARIC Study, in which only 103 experienced an
ICH. The 10-year cumulative incidence for ICH
was approximately one-ninth of the 10-year
cumulative incidence of IS in all studies (table 2).
Hazard ratios. Sex, diabetes, prior coronary heart dis-
ease, waist-to-hip ratio, and estimated glomerular
Table 1 Baseline characteristics
ARIC Study (n 5 15,170) Rotterdam Study (n 5 6,910) CHS (n 5 5,413)
Age, y, median (IQR) 54 (49, 59) 68 (62, 76) 71 (68, 76)
Sex, male, n (%) 6,828 (45) 2,633 (38) 2,240 (41)
African American ethnicity, n (%) 4,072 (27) 0 838 (15)
Systolic BP, mm Hg, median (IQR) 119 (108, 131) 137 (123, 153) 134 (121, 149)
Missing data, n (%) 14 (0) 728 (11) 9 (0)
Diastolic BP, mm Hg, median (IQR) 70 (66, 80) 73 (66, 81) 70 (63, 78)
Missing data, n (%) 16 (0) 729 (11) 16 (0)
Antihypertensive medication use, n (%) 3,787 (25) 2,085 (30) 2,487 (46)
Missing data, n (%) 85 (1) 6 (0) 7 (0)
Current smoking, n (%) 3,981 (26) 1,520 (23) 654 (12)
Missing data, n (%) 15 (0) 205 (3) 6 (0)
Diabetes mellitus, n (%) 1,780 (12) 637 (11) 843 (16)
Missing data, n (%) 141 (1) 975 (14) 55 (1)
Prior coronary heart disease, n (%) 1,707 (12) 949 (16) 1,071 (20)
Missing data, n (%) 330 (2) 1,074 (15) 47 (1)
Total cholesterol, mmol/L, median (IQR) 5.5 (4.8, 6.2) 6.6 (5.8, 7.4) 5.5 (4.8, 6.1)
Missing data, n (%) 239 (2) 700 (10) 46 (1)
HDL-C, mmol/L, median (IQR) 1.3 (1.0, 1.6) 1.3 (1.1, 1.6) 1.3 (1.1, 1.6)
Missing data, n (%) 237 (2) 726 (11) 54 (1)
BMI, kg/m2, median (IQR) 26.9 (24.0, 30.4) 26.0 (23.8, 28.4) 26.1 (23.5, 29.2)
Missing values, n (%) 25 (0) 772 (11) 17 (0)
Waist-to-hip ratio, median (IQR) 0.94 (0.88, 0.98) 0.90 (0.84, 0.97) 0.94 (0.87, 0.98)
Missing values, n (%) 28 (0) 1,081 (16) 34 (1)
eGFR, mL/min/1.73 m2, median (IQR) 89.0 (79.7, 102.3) 77.3 (67.3, 87.7) 76.7 (64.2, 89.9)
Missing values, n (%) 146 (1) 2,254 (33) 59 (1)
Statin therapy use, n (%) 85 (1) 141 (2) 121 (2)
Missing values, n (%) 115 (1) 6 (0) 7 (0)
Abbreviations: ARIC 5 Atherosclerosis Risk in Communities; BMI 5 body mass index; BP 5 blood pressure; CHS 5 Car-
diovascular Health Study; eGFR5 estimated glomerular filtration rate; HDL-C5 high-density lipoprotein cholesterol; IQR5
interquartile range.
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filtration rate were not found to be statistically
significant and were excluded from ICH models,
whereas these were included in IS models. Table 3
shows the multivariable-adjusted HRs and 95%
CIs for incident ICH and IS events (see table e-7
for competing death). For both ICH and IS,
replacement of total and HDL-C by total cholesterol/
HDL-C ratio and the simultaneous inclusion of systolic
and diastolic blood pressure (despite correlations of
0.69, 0.59, and 0.51 in ARIC, Rotterdam, and CHS
cohorts) improved the Akaike Information Criterion
(figures e-1 through e-4 show the multivariable
adjusted relations with ICH and IS event rates). The
extended ICH model is reported without BMI,
although BMI statistically significantly decreased the
ICH hazard: 0.97 (95% CI 0.94–0.99) per unit




(n 5 6,910) CHS (n 5 5,446)
Overall incident events, n
Intracerebral hemorrhage 103 99 123
Ischemic stroke 920 820 819
Competing nonstroke death 3,727 3,035 3,147
10-y incident events, n (cumulative incidence, %)
Intracerebral hemorrhage 42 (0.3) 57 (0.8) 62 (1.1)
Ischemic stroke 360 (2.4) 523 (7.6) 530 (9.8)
Competing nonstroke death 1,179 (7.8) 1,814 (26.3) 1,433 (26.5)
Median follow-up duration, y (IQR) 20.7 (17.5, 21.7) 14.3 (7.2, 16.2) 12.8 (7.4, 18.3)
Person-years of follow-up 279,741.9 81,997.6 66,325.4
Abbreviations: ARIC 5 Atherosclerosis Risk in Communities; CHS 5 Cardiovascular Health Study; IQR 5 interquartile range.
Table 3 Included predictors and hazard ratios (95% confidence intervals)
Predictor Basic ICH Extended ICH Basic IS Extended IS
Age per 10-y increase 1.85 (1.55–2.21) 1.95 (1.63–2.35) — —
In men — — 1.89 (1.75–2.05) 1.87 (1.72–2.04)
In women — — 2.13 (1.99–2.28) 2.09 (1.94–2.25)
Sex, male — — 2.62 (1.55–4.42) 2.21 (1.31–3.74)
African American 1.78 (1.33–2.39) 1.54 (1.14–2.09) 1.34 (1.20–1.50) 1.35 (1.20–1.51)
Current smoking 1.53 (1.17–2.00) 1.51 (1.15–1.98) 1.63 (1.49–1.80) 1.62 (1.47–1.78)
Diabetes — — 1.77 (1.60–1.95) 1.67 (1.52–1.85)
Antihypertensive medication use 5.53 (1.26–24.32) 5.59 (1.32–23.67) 3.83 (2.33–6.30) 3.31 (2.02–5.45)
Systolic BP per 10 mm Hg increase
If medication use 1.10 (1.01–1.20) 1.04 (0.95–1.15) 1.11 (1.08–1.14) 1.09 (1.06–1.13)
If no medication use 1.26 (1.19–1.34) 1.19 (1.11–1.29) 1.20 (1.17–1.23) 1.17 (1.14–1.21)
Prior coronary heart disease
In men — — 1.64 (1.42–1.89) 1.60 (1.39–1.85)
In women — — 1.22 (1.07–1.40) 1.19 (1.04–1.37)
Diastolic BP per 10 mm Hg increase — 0.25 (0.11–0.55) — 0.71 (0.52–0.98)
Diastolic BP per 10 mm Hg increase squared — 1.10 (1.05–1.16) — 1.03 (1.00–1.05)
Total cholesterol/HDL-C ratio — 0.55 (0.39–0.78) — 1.05 (1.03–1.08)
Total cholesterol/HDL-C ratio squared — 1.05 (1.01–1.08) — —
GFR per 10 mL/min/1.73 m2 increase — — — 0.77 (0.70–0.86)
GFR squared — — — 1.01 (1.01–1.02)
Waist-to-hip ratio per 0.1 increase — — — 1.11 (1.05–1.18)
Abbreviations: BP 5 blood pressure; GFR 5 glomerular filtration rate; HDL-C 5 high-density lipoprotein cholesterol; ICH 5 intracerebral hemorrhage; IS 5
ischemic stroke.
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increase. However, the BMI association varied
significantly across the 3 studies (see table e-2)
and exclusion improved the cross-validated model
performance (see table e-5). BMI was removed
from the extended IS model because it was not
statistically significant (p 5 0.27).
Midrange total cholesterol/HDL-C ratio values
as compared with low and high values decreased
ICH risk, whereas high total cholesterol/HDL-C
ratio monotonically increased IS risk (see figures
e-2 and e-4). The association of the total cholesterol/
HDL-C ratio statistically differed across stroke types
(p , 0.001). The HRs for ICH additionally cen-
sored for IS and vice versa are given in tables e-8 and
e-9; these did not largely differ from those shown in
table 3.
Model performance. For ICH prediction, C statistics of
cumulative incidence functions were higher than C
statistics of standard survival models (see tables 4
and e-10). For IS prediction, C statistics of both sta-
tistical methods were comparable. Extending the
basic cumulative incidence functions generally led
to small improvements in C statistics, ranging from
0.001 to 0.020 for ICH, and 0.001 to 0.009 for IS.
The continuous total net reclassification improve-
ments were positive, with more pronounced changes
in the ARIC cohort. Improvements in C statistics
were reproduced by cross-validation except for IS
predictions in Rotterdam Study data (table 4). C
statistics for any stroke predictions were similar to
IS predictions, and did not improve with model
extension (table e-11).
As compared with standard survival models, cali-
bration generally improved using cumulative incidence
functions, especially within the elderly, except for ICH
prediction below the second age tertile in the CHS
cohort (see table e-10 and figures e-5 to e-8). Overall,
model calibration did not differ to a relevant extent
between basic and extended models for both ICH
and IS prediction (figures e-5 to e-8). Results on
calibration by the any-stroke cumulative incidence
functions were similar to those for IS prediction
(table e-11).
Predicted ICH risk tended to increase with IS
risk for each study, but the correlation between
both predicted risks was moderate in ARIC, Rotter-
dam, and CHS cohorts (r 5 0.57, 0.59, 0.37,
respectively; figure 1). The Excel risk calculator
Table 4 Prognostic performance
Model development in ARIC, Rotterdam, and CHS Basic ICH model Extended ICH model Basic IS model Extended IS model
Evaluated in ARIC Study
C statistic (95% CI) 0.805 (0.739, 0.871) 0.811 (0.743, 0.879) 0.789 (0.768, 0.811) 0.798 (0.777, 0.819)
Total NRI (95% CI) — 0.28 (20.06, 0.62) — 0.29 (0.18, 0.39)
Event NRI (95% CI) — 0.10 (20.17, 0.47) — 0.28 (0.17, 0.38)
Nonevent NRI (95% CI) — 0.18 (0.17, 0.20) — 0.01 (0.00, 0.03)
Evaluated in Rotterdam Study
C statistic (95% CI) 0.625 (0.555, 0.695) 0.626 (0.556, 0.696) 0.696 (0.677, 0.716) 0.697 (0.677, 0.717)
Total NRI (95% CI) — 0.19 (20.03, 0.45) — 0.15 (0.06, 0.23)
Event NRI (95% CI) — 20.16 (20.37, 0.18) — 0.11 (0.02, 0.21)
Nonevent NRI (95% CI) — 0.35 (0.31, 0.37) — 0.03 (0.01, 0.07)
Evaluated in CHS
C statistic (95% CI) 0.676 (0.603, 0.750) 0.696 (0.624, 0.767) 0.658 (0.637, 0.679) 0.663 (0.642, 0.684)
Total NRI (95% CI) — 0.04 (20.26, 0.31) — 0.05 (20.026, 0.13)
Event NRI (95% CI) — 0.03 (20.23, 0.30) — 20.20 (20.31, 20.12)
Nonevent NRI (95% CI) — 0.00 (20.02, 0.03) — 0.25 (0.23, 0.28)
Cross-validation
C statistic (95% CI) in ARIC Study 0.729 (0.652, 0.806) 0.734 (0.653, 0.814) 0.760 (0.737, 0.783) 0.768 (0.745, 0.790)
C statistic (95% CI) in Rotterdam Study 0.622 (0.552, 0.693) 0.626 (0.556, 0.696) 0.694 (0.674, 0.713) 0.692 (0.672, 0.712)
C statistic (95% CI) in CHS 0.667 (0.595, 0.740) 0.684 (0.614, 0.753) 0.651 (0.630, 0.672) 0.654 (0.633, 0.676)
Abbreviations: ARIC 5 Atherosclerosis Risk in Communities; CHS 5 Cardiovascular Health Study; CI 5 confidence interval; ICH 5 intracerebral hemor-
rhage; IS 5 ischemic stroke; NRI 5 net reclassification improvement.
Event NRI is calculated as the difference in the probability being reclassified upward and the probability being reclassified downward conditional on
experiencing the event within 10 years: p (up│event) 2 p (down│event). Nonevent NRI is calculated as the difference in the probability being reclassified
downward and the probability being reclassified upward conditional on not experiencing the event within 10 years: p (down│event) 2 p (up│event). Total
NRI is calculated as the sum of event NRI and nonevent NRI.
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for predicting the 10-year cumulative incidence of
any stroke subdivided into ICH and IS components
can be accessed online (appendix e-2). HRs used in
the calculator are provided in tables e-7 to e-9.
DISCUSSION In this study, we developed and cross-
validated 10-year ICH and IS risk models within
middle-aged and elderly individuals. As compared
with standard survival analysis, the cumulative
incidence functions showed improved discriminative
ability for ICH prediction and better model
calibration, especially in the elderly. Extending basic
nonlaboratory models led to limited improvement
of discriminative ability. By using our cumulative
incidence functions, individuals can be identified
with low 10-year IS risk but high ICH risk, and
vice versa.
Studies on hemorrhagic stroke prediction are
scarce. By performing a systematic literature search
(see appendix e-1), we found only 2 studies, both
conducted in Chinese populations. One study24 was
performed in a cohort of 4,400 steelworkers free of
stroke at baseline with an average age of 45 years. The
number of hemorrhagic strokes was low: 33 in the
development set and 15 in the validation set.
Multivariable-adjusted HRs of age (1.89 per 10 years)
and systolic blood pressure (1.22 per 10 mm Hg)
were similar to ours. For diastolic blood pressure
(1.49 per 10 mm Hg) and total cholesterol (1.00
per mmol/L), nonlinearity was not explored, and
therefore associations are not comparable with ours.
In addition, the model was not validated in the gen-
eral population and the elderly. In the other study,25
major bleeding risk scoring schemes designed for pa-
tients with atrial fibrillation were validated in 3,602
individuals without atrial fibrillation. C statistics of
the various risk scores ranged from 0.59 to 0.72. Indi-
viduals with previous stroke were, however, not
excluded, and ICH event ascertainment was registry-
based. Other prognostic studies focused on either assess-
ment of any stroke risk3,4,14,16,26–32 or IS risk5,6,20,33,34
usually within a time horizon of 5 to 10 years.
In contrast, we developed models for the separate
10-year risk assessment of ICH and IS while consid-
ering competing risks. By combining data from 3
large population-based cohorts, we acquired a suffi-
cient number of ICH events for multivariable predic-
tion modeling. The number of ICH events was low in
the ARIC Study, probably explained by the younger
age of this cohort. Furthermore, we included elderly
individuals older than 75 years. Especially in the
elderly, competing risks become relevant, because
the competing death rate rapidly increases. We dem-
onstrated that also in the elderly, predictions were
well calibrated as opposed to predictions using stan-
dard survival analysis.
Figure 1 Contribution of intracerebral hemorrhage and ischemic stroke to 10-year any stroke incidence
ARIC 5 Atherosclerosis Risk in Communities; CHS 5 Cardiovascular Health Study.
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Our results must be interpreted in the light of some
limitations. First, we did not consider biomarkers,
genetic risk factors, and imaging tests. For example,
studies have demonstrated an independent association
of C-reactive protein with IS but not ICH risk,35 and
carotid intima-media thickness measurement and
APOE genotype with both ICH and IS risk.36,37
However, carotid intima-media thickness and APOE
genotype are generally difficult to assess during an
office-based risk assessment, which would limit the
translation to clinical practice, and C-reactive protein
was not available as a baseline variable in the ARIC
Study. Second, neuroimaging was not performed in all
participants with stroke symptoms. Consequently, a
proportion of strokes were not further specified. We
included these as IS, which could have led to a small
overestimation of the IS risk and underestimation of
ICH risk. Third, the quality of the individual studies
may have influenced the overall validity of the results.
For example, the Rotterdam Study had more missing
values for the included predictors than the other 2
cohorts. Because of the computational demand of con-
structing the cumulative incidence function, it was
infeasible to perform multiple imputation. Therefore,
the precision of our models is subject to a small over-
estimation. In addition, validity of our results is ham-
pered if the missingness was actually nonrandom.
Fourth, the baseline age ranges of the ARIC, Rot-
terdam, and CHS cohorts did not entirely overlap.
As a consequence, the age association was not fully
determined by the 3 datasets combined. Finally, we
excluded individuals with stroke, atrial fibrillation,
or anticoagulation use at baseline, and individuals
who were not Caucasian and not African American,
such as Asian and Hispanic participants. Also, we
did not consider use of antiplatelet and statin ther-
apy in the analysis. The effect of these preventive
drugs should have been captured in the baseline sur-
vival function or within the associations of included
predictors. The validity of our predictions can thus
be affected if the use of these drugs differs by pop-
ulation or varies over time because of changing med-
ical practice. Consequently, our predictions should
be validated in other and more recent populations.
For patients with atrial fibrillation, clinicians should
use the specific stroke and bleeding risk models val-
idated for this population.
We evaluated extension of a basic nonlaboratory
model using C statistic as a criterion. The C statistic
would improve if a predictor is added that increases
risk in early cases and/or decreases risk in late cases
and controls. The impact on the C statistic depends
both on the HR of the added predictor and its distri-
bution in the context of included predictors.38
Because we evaluated the heterogeneity of associations
within sensitivity analyses, the varying distribution of
predictor values across the 3 cohorts must have led to
the differences in (changes of) the C statistic. However,
because discriminative ability generally improved for
all 3 cohorts, and the added predictors are expected
to incur limited extra costs and potential harms, we
recommend the use of the extended models as the
preferred choice.
Specifying whether a first stroke is ICH or IS is
clinically valuable. More refined estimates of the
expected benefits and harms can be made about pre-
ventive interventions with different effects on ICH
and IS risk. For example, aspirin use is recommended
when the potential benefit of reduction in IS out-
weighs the bleeding risks.39 This trade-off is especially
relevant in the elderly,40 making well-calibrated pre-
dictions at older ages more important. Our cumula-
tive incidence functions may therefore be useful to
refine communication of the expected benefit (by
number of IS events avoided) and harm (by number
of induced ICH events in addition to gastrointestinal
bleedings) to support shared decision-making. How-
ever, differences in case-fatality rate of ICH and IS
should be considered as well. In this context, we
anticipate that our prediction models for 10-year
ICH and IS risk are useful to further specify an in-
dividual’s stroke risk.
AUTHOR CONTRIBUTIONS
Dr. Ferket: drafting the manuscript for content, study concept and
design, analysis and interpretation of data. Dr. van Kempen: revising
the manuscript for content, interpretation of data. Dr. Wieberdink: revis-
ing the manuscript for content. Dr. Steyerberg: study concept and design,
revising the manuscript for content, interpretation of data. Dr. Koudstaal,
Dr. Hofman, Dr. Shahar, Dr. Gottesman, Dr. Rosamond, Dr. Kizer,
Dr. Kronmal, and Dr. Psaty: revising the manuscript for content.
Dr. Longstreth, Jr.: study concept and design, revising the manuscript
for content. Dr. Mosley: revising the manuscript for content. Dr. Folsom,
Dr. Hunink, and Dr. Ikram: study concept and design, revising the man-
uscript for content.
ACKNOWLEDGMENT
The authors thank David van Klaveren and Yvonne Vergouwe (Depart-
ment of Public Health, Erasmus MC) for their valuable methodologic
advice, and Irene Doherty (ARIC Study) and Tony Wilsdon (CHS) for
preparing the ARIC and CHS datasets. The contributions of inhabitants,
general practitioners, and pharmacists of the Ommoord district to the Rot-
terdam Study are gratefully acknowledged.
STUDY FUNDING
The Atherosclerosis Risk in Communities Study is performed as a collaborative
study supported by National Heart, Lung, and Blood Institute (contracts
HHSN268201100005C, HHSN268201100006C, HHSN268201100007C,
HHSN268201100008C, HHSN268201100009C, HHSN268201100010C,
HHSN268201100011C, and HHSN268201100012C). The authors thank
the staff and participants of the ARIC Study for their important contributions.
The Rotterdam Study is supported by the Erasmus Medical Center Rotterdam,
the Erasmus University Rotterdam, the Netherlands Organization for Scientific
Research (NWO), The Netherlands Organization for Health Research and
Development (ZonMW), the Research Institute for Diseases in the
Elderly (RIDE), the Ministry of Education, Culture and Science, the
Ministry of Health, Welfare and Sports, the European Commission
(DG XII), and the Municipality of Rotterdam. B.S.F. was funded
through the Netherlands Organization for Scientific Research
1810 Neurology 82 May 20, 2014
(NWO) training grant 022.002.023. The Cardiovascular Health Study was
supported by contracts HHSN268201200036C, HHSN268200800007C,
N01 HC55222, N01HC85079, N01HC85080, N01HC85081,
N01HC85082, N01HC85083, N01HC85086, and grant HL080295
from the National Heart, Lung, and Blood Institute, with additional con-
tribution from the National Institute of Neurological Disorders and Stroke.
Additional support was provided by AG023629 from the National Institute
on Aging. A full list of principal CHS investigators and institutions can be
found at http://www.chs-nhlbi.org/PI.htm.
DISCLOSURE
B. Ferket, B. van Kempen, R. Wieberdink, E. Steyerberg, P. Koudstaal,
A. Hofman, E. Shahar, R. Gottesman, and W. Rosamond report no dis-
closures relevant to the manuscript. J. Kizer has provided expert witness
consultation to Pfizer relating to Prempro and stroke. R. Kronmal reports
no disclosures relevant to the manuscript. B. Psaty serves on the DSMB
of a clinical trial of a device funded by the manufacturer (Zoll LifeCor)
and on the Steering Committee of the Yale Open Data Access Project
funded by Johnson & Johnson. W. Longstreth, Jr., T. Mosley,
A. Folsom, M. Hunink, and M. Ikram report no disclosures relevant
to the manuscript. Go to Neurology.org for full disclosures.
DISCLAIMER
The funding sources had no role in the design, conduct, or analysis of
this study or in the decision to submit the article for publication.
Received August 5, 2013. Accepted in final form February 19, 2014.
REFERENCES
1. OECD.StatExtracts. OECD health data 2011 [on-
line]. Available at: http://stats.oecd.org/index.aspx?
DataSetCode5HEALTH_STAT. Accessed August 5, 2013.
2. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL,
Parag V. Worldwide stroke incidence and early case fatality
reported in 56 population-based studies: a systematic
review. Lancet Neurol 2009;8:355–369.
3. Wolf PA, D’Agostino RB, Belanger AJ, Kannel WB. Prob-
ability of stroke: a risk profile from the Framingham
Study. Stroke 1991;22:312–318.
4. Lumley T, Kronmal RA, Cushman M, Manolio TA,
Goldstein S. A stroke prediction score in the elderly: val-
idation and Web-based application. J Clin Epidemiol
2002;55:129–136.
5. Chambless LE, Heiss G, Shahar E, Earp MJ, Toole J.
Prediction of ischemic stroke risk in the Atherosclerosis
Risk in Communities Study. Am J Epidemiol 2004;160:
259–269.
6. Assmann G, Schulte H, Cullen P, Seedorf U. Assessing
risk of myocardial infarction and stroke: new data from the
Prospective Cardiovascular Munster (PROCAM) Study.
Eur J Clin Invest 2007;37:925–932.
7. Leppala JM, Virtamo J, Fogelholm R, Albanes D,
Heinonen OP. Different risk factors for different stroke
subtypes: association of blood pressure, cholesterol, and
antioxidants. Stroke 1999;30:2535–2540.
8. Baigent C, Blackwell L, Collins R, et al; Antithrombotic
Trialists’ (ATT) Collaboration. Aspirin in the primary and
secondary prevention of vascular disease: collaborative
meta-analysis of individual participant data from rando-
mised trials. Lancet 2009;373:1849–1860.
9. Koller MT, Raatz H, Steyerberg EW, Wolbers M. Com-
peting risks and the clinical community: irrelevance or
ignorance? Stat Med 2012;31:1089–1097.
10. The ARIC Investigators. The Atherosclerosis Risk in
Communities (ARIC) Study: design and objectives. Am
J Epidemiol 1989;129:687–702.
11. Hofman A, van Duijn CM, Franco OH, et al. The Rot-
terdam Study: 2012 objectives and design update. Eur J
Epidemiol 2011;26:657–686.
12. Fried LP, Borhani NO, Enright P, et al. The Cardiovas-
cular Health Study: design and rationale. Ann Epidemiol
1991;1:263–276.
13. Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines
for the primary prevention of stroke: a guideline for
healthcare professionals from the American Heart Associa-
tion/American Stroke Association. Stroke 2011;42:517–
584.
14. D’Agostino RB, Wolf PA, Belanger AJ, Kannel WB.
Stroke risk profile: adjustment for antihypertensive medi-
cation. The Framingham Study. Stroke 1994;25:40–43.
15. Sturgeon JD, Folsom AR, Longstreth WT Jr, Shahar E,
Rosamond WD, Cushman M. Risk factors for intracere-
bral hemorrhage in a pooled prospective study. Stroke
2007;38:2718–2725.
16. Voko Z, Hollander M, Koudstaal PJ, Hofman A,
Breteler MM. How do American stroke risk functions
perform in a Western European population? Neuroepi-
demiology 2004;23:247–253.
17. Rosamond WD, Folsom AR, Chambless LE, et al. Stroke
incidence and survival among middle-aged adults: 9-year
follow-up of the Atherosclerosis Risk in Communities
(ARIC) cohort. Stroke 1999;30:736–743.
18. Ives DG, Fitzpatrick AL, Bild DE, et al. Surveillance and
ascertainment of cardiovascular events. The Cardiovascular
Health Study. Ann Epidemiol 1995;5:278–285.
19. Wieberdink RG, Ikram MA, Hofman A, Koudstaal PJ,
Breteler MM. Trends in stroke incidence rates and stroke
risk factors in Rotterdam, the Netherlands from 1990 to
2008. Eur J Epidemiol 2012;27:287–295.
20. Hippisley-Cox J, Coupland C, Brindle P. Derivation and
validation of QStroke score for predicting risk of ischaemic
stroke in primary care and comparison with other risk
scores: a prospective open cohort study. BMJ 2013;346:
f2573.
21. Franklin SS, Lopez VA, Wong ND, et al. Single versus
combined blood pressure components and risk for cardi-
ovascular disease: the Framingham Heart Study. Circula-
tion 2009;119:243–250.
22. Wolbers M, Koller MT, Witteman JC, Steyerberg EW.
Prognostic models with competing risks: methods and
application to coronary risk prediction. Epidemiology
2009;20:555–561.
23. Pencina MJ, D’Agostino RB Sr, Steyerberg EW. Exten-
sions of net reclassification improvement calculations to
measure usefulness of new biomarkers. Stat Med 2011;
30:11–21.
24. Zhang XF, Attia J, D’Este C, Yu XH, Wu XG. A risk
score predicted coronary heart disease and stroke in a Chi-
nese cohort. J Clin Epidemiol 2005;58:951–958.
25. Lip GY, Lin HJ, Hsu HC, et al. Comparative assessment of
the HAS-BLED score with other published bleeding risk
scoring schemes, for intracranial haemorrhage risk in a
non-atrial fibrillation population: the Chin-Shan Commu-
nity Cohort Study. Int J Cardiol 2013;168:1832–1836.
26. Anderson KM, Odell PM, Wilson PW, Kannel WB. Car-
diovascular disease risk profiles. Am Heart J 1991;121(1 pt
2):293–298.
27. Bineau S, Dufouil C, Helmer C, et al. Framingham stroke
risk function in a large population-based cohort of elderly
people: the 3C Study. Stroke 2009;40:1564–1570.
Neurology 82 May 20, 2014 1811
28. Borglykke A, Andreasen AH, Kuulasmaa K, et al. Stroke
risk estimation across nine European countries in the
MORGAM project. Heart 2010;96:1997–2004.
29. Jee SH, Park JW, Lee SY, et al. Stroke risk prediction
model: a risk profile from the Korean study. Atherosclero-
sis 2008;197:318–325.
30. Moons KG, Bots ML, Salonen JT, et al. Prediction of stroke
in the general population in Europe (EUROSTROKE): is
there a role for fibrinogen and electrocardiography?
J Epidemiol Community Health 2002;(56 suppl 1):
i30–i36.
31. Truelsen T, Lindenstrom E, Boysen G. Comparison of prob-
ability of stroke between the Copenhagen City Heart Study
and the Framingham Study. Stroke 1994;25:802–807.
32. Chien KL, Su TC, Hsu HC, et al. Constructing the pre-
diction model for the risk of stroke in a Chinese popula-
tion: report from a cohort study in Taiwan. Stroke 2010;
41:1858–1864.
33. Simons LA, McCallum J, Friedlander Y, Simons J. Risk
factors for ischemic stroke: Dubbo Study of the Elderly.
Stroke 1998;29:1341–1346.
34. Qiao Q, Gao W, Laatikainen T, Vartiainen E. Layperson-
oriented vs. clinical-based models for prediction of inci-
dence of ischemic stroke: National FINRISK Study. Int J
Stroke 2012;7:662–668.
35. Kaptoge S, Di Angelantonio E, Lowe G, et al; Emerging
Risk Factors Collaboration. C-reactive protein concentra-
tion and risk of coronary heart disease, stroke, and mor-
tality: an individual participant meta-analysis. Lancet
2010;375:132–140.
36. Ohira T, Shahar E, Iso H, et al. Carotid artery wall thick-
ness and risk of stroke subtypes: the Atherosclerosis Risk in
Communities Study. Stroke 2011;42:397–403.
37. Sudlow C, Martinez Gonzalez NA, Kim J, Clark C. Does
apolipoprotein E genotype influence the risk of ischemic
stroke, intracerebral hemorrhage, or subarachnoid hemor-
rhage? Systematic review and meta-analyses of 31 studies
among 5961 cases and 17,965 controls. Stroke 2006;37:
364–370.
38. Demler OV, Pencina MJ, D’Agostino RB Sr. Impact of
correlation on predictive ability of biomarkers. Stat Med
Epub May 3 2013.
39. US Preventive Services Task Force. Aspirin for the preven-
tion of cardiovascular disease: U.S. Preventive Services
Task Force recommendation statement. Ann Intern Med
2009;150:396–404.
40. Nelson MR, Liew D, Bertram M, Vos T. Epidemiological
modelling of routine use of low dose aspirin for the pri-
mary prevention of coronary heart disease and stroke in
those aged $70. BMJ 2005;330:1306.
Free Michael J. Fox DVD, Video on Parkinson’s Disease
The AAN and the American Brain Foundation present actor and Parkinson’s disease patient
Michael J. Fox hosting Parkinson’s Disease: A Guide for Patients and Families. This new patient
education video is now available free to members and the public, either on DVD or online. The
free DVD can be ordered while supplies last by visiting AAN.com/view/PatientEducationVideos or
calling (800) 879-1960. The video can be viewed online at YouTube.com/AANChannel with other
patient education DVDs produced by the AAN.
Guide the Future of Neurology—Become a Mentor!
The Academy’s Neurology Career Center is working to bring experienced members together with
members who seek guidance on their career path. AAN Mentor Connect needs volunteer Mentors
who are willing to share their expertise, insights, and experiences with Mentees.
This flexible program, available only to AAN members, matches prospective Mentors and Mentees,
and enables you to develop a plan with the Mentee that has a mutually agreeable schedule and
expectations.
Enjoy the personal satisfaction of making a valued contribution to the career of a fellow AAN
member. Visit www.aan.com/view/Mentor to learn more and register to be a Mentor today.
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